These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6096517)

  • 1. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
    Jackson DV; Zekan PJ; Caldwell RD; Slatkoff ML; Harding RW; Case LD; Hopkins JO; Muss HB; Richards F; White DR
    J Clin Oncol; 1984 Dec; 2(12):1343-51. PubMed ID: 6096517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.
    Collins C; Higano CS; Livingston RB; Griffin BR; Keppen MD; Miller TP
    Cancer Chemother Pharmacol; 1989; 24(2):128-32. PubMed ID: 2543513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
    Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
    J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213.
    Jackson DV; Wells HB; White DR; Muss HB; Richards F; Cooper MR; Stuart JJ; Pope EK; Spurr CL
    Am J Clin Oncol; 1983 Jun; 6(3):327-30. PubMed ID: 6303106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
    Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
    Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
    Spitzer G; Farha P; Valdivieso M; Dicke K; Zander A; Vellekoop L; Murphy WK; Dhingra HM; Umsawasdi T; Chiuten D
    J Clin Oncol; 1986 Jan; 4(1):4-13. PubMed ID: 3510281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
    Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
    J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
    Daniels JR; Chak LY; Sikic BI; Lockbaum P; Kohler M; Carter SK; Reynolds R; Bohnen R; Gandara D; Yu J
    J Clin Oncol; 1984 Nov; 2(11):1192-9. PubMed ID: 6092554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of long-term survival in extensive small-cell lung cancer.
    Jackson DV; Case LD; Zekan PJ; Powell BL; Caldwell RD; Bearden JD; Nelson EC; Muss HB; Cooper MR; Richards F
    J Clin Oncol; 1988 Jul; 6(7):1161-9. PubMed ID: 2839632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy.
    Goodman GE; Miller TP; Manning MM; Davis SL; McMahon LJ
    J Clin Oncol; 1983 Aug; 1(8):483-8. PubMed ID: 6321685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.